2-(3,4-Dihydroxy-benzylidene)-benzofuran-3-one,Sphingosine Kinase Inhibitor V
Modify Date: 2025-09-15 14:49:00
2-(3,4-Dihydroxy-benzylidene)-benzofuran-3-one,Sphingosine Kinase Inhibitor V structure
|
Common Name | 2-(3,4-Dihydroxy-benzylidene)-benzofuran-3-one,Sphingosine Kinase Inhibitor V | ||
|---|---|---|---|---|
| CAS Number | 24418-86-8 | Molecular Weight | 254.24 | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | C15H10O4 | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
Use of 2-(3,4-Dihydroxy-benzylidene)-benzofuran-3-one,Sphingosine Kinase Inhibitor VSKI V is a noncompetitive and potent non-lipid sphingosine kinase (SPHK; SK) inhibitor with an IC50 of 2 μM for GST-hSK. SKI V potently inhibits PI3K with an IC50 of 6 μM for hPI3k. SKI V decreases formation of the mitogenic second messenger sphingosine-1-phosphate (S1P). SKI V induces apoptosis and has antitumor activity[1][2]. |
| Name | SKI V |
|---|---|
| Synonym | More Synonyms |
| Description | SKI V is a noncompetitive and potent non-lipid sphingosine kinase (SPHK; SK) inhibitor with an IC50 of 2 μM for GST-hSK. SKI V potently inhibits PI3K with an IC50 of 6 μM for hPI3k. SKI V decreases formation of the mitogenic second messenger sphingosine-1-phosphate (S1P). SKI V induces apoptosis and has antitumor activity[1][2]. |
|---|---|
| Related Catalog | |
| Target |
IC50: 2 μM (GST-hSK), 6 μM (hPI3k) and 80 μM (ERK2)[1] |
| In Vitro | SKI V has weak activity toward ERK2 (IC50 of 80 μM for hERK2) and does not inhibit PKC-α[1]. SKI V (10 μM; for 24 hours) inhibits cancer cell proliferation and induces apoptosis[1]. SKI V (0.2, 1, 5 μM; pretreated for 1 hour) decreases phospho-Akt and phospho-MEK levels. Near-confluent cultures of JC cells are serum-starved for 16 hours, followed by pretreatment SKI V for 1 hour[2]. SKI V has IC50s for inhibition of sphingosine kinase (SK) and tumor cell proliferation of ∼2 μM[1]. SKI V (20 μg/ml) inhibits not only purified but endogenous SK in in MDA-MB-231 cells[1]. SKI V (0.2, 1, 5 μM) inhibits intracellular S1P formation in JC cells in a dose-dependent fashion[2]. Cell Proliferation Assay[1] Cell Line: T24 tumor cells Concentration: 10 μM Incubation Time: For 24 hours Result: Inhibited cancer cell proliferation. Apoptosis Analysis[1] Cell Line: T24 tumor cells Concentration: 10 μM Incubation Time: For 24 hours Result: Induced apoptosis. Western Blot Analysis[2] Cell Line: JC cells Concentration: 0.2, 1, 5 μM Incubation Time: Pretreated for 1 hour Result: Decreased phospho-Akt and phospho-MEK levels. |
| In Vivo | SKI V (75 mg/kg; i.p.; days 1, 5, 9, 15) significantly lowers tumor growth (>50% decreased at day 18) than control animals[1]. Animal Model: 6-8 weeks old BALB/c female mice with JC mammary adenocarcinoma cells[1] Dosage: 75 mg/kg Administration: IP; days 1, 5, 9, 15 Result: Tumor growth was significantly lower (>50% decreased at day 18) than tumor growth in control animals. |
| References |
| Molecular Formula | C15H10O4 |
|---|---|
| Molecular Weight | 254.24 |
| Hazard Codes | Xi |
|---|
| MFCD07772193 |